Preventing graft-versus-host disease after half-matched stem cell transplant
Treatments studied
Part of Immune system & allergy clinical trials.
This trial tests whether a new test can help prevent a serious complication called graft-versus-host disease (where donor cells attack your body) after a half-matched stem cell transplant. If you qualify, you may receive the study drug ruxolitinib to lower your risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 17 years old or older.
- You need to be getting a half-matched (haploidentical) stem cell transplant.
- You must be able to take medications by mouth (as pills or liquids)
- You must not have had more than one stem cell transplant before this one.
- You must not be allergic to, or unable to tolerate, the drug ruxolitinib.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the drug ruxolitinib, given based on a blood test that predicts risk, can prevent chronic graft-versus-host disease (cGVHD) after a stem cell transplant. It may help people who have a higher risk of developing this complication.
This trial tests whether a drug called ruxolitinib, with or without another drug called abatacept, can prevent graft-versus-host disease and cytokine release syndrome after a half-matched stem cell transplant from a family donor. It's for people with certain blood cancers who are getting this type of transplant.
This trial tests a drug called ruxolitinib for treating acute graft-versus-host disease (aGVHD), a common complication after a stem cell transplant. It may help control the immune reaction without using high doses of steroids.
This trial tests a combination of two drugs, ruxolitinib and PTCy, to prevent graft-versus-host disease (a common complication) in children receiving a stem cell transplant for inborn errors of immunity. The goal is to make the transplant safer and more effective.
This trial tests whether the drug ruxolitinib, given before and after a stem cell transplant, can help prevent graft-versus-host disease (GVHD) in people with blood cancers. GVHD is a common complication where donor cells attack the patient's body.
This trial tests a new approach using the drug ruxolitinib to help a half-matched bone marrow transplant work better for people with severe sickle cell disease. It aims to reduce complications and improve outcomes.
Hear when a new Transplant-Related Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.